Therefore, our data discard the use of inhibitors of the RAF-MEK-ERK1/2 signalling pathway in RCC and support the use of pro-autophagic compounds, opening new therapeutic opportunities for Renal Cell Carcinoma. The gene discussed is MAPK3; the disease is hereditary clear cell renal cell carcinoma.